AbGenomics B.V Taiwan Branch
conventional treatment(AbGenomics B.V Taiwan Branch)은 Graft vs Host Disease 표적 치료제로, Graft vs Host Disease 영역에서 개발·상용화 중입니다. 작용기전: targets and cellular pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 41.33% (ClinicalTrials.gov NCT03486457). 차별점: novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies.
Graft vs Host Disease
Graft vs Host Disease
Active
novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies
targets and cellular pathway
apoptosis, and changes in key cell markers were evaluated
PD-1 combination therapy follow
resistance towards conventional treatment techniques
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
AbGenomics B.V Taiwan Branch
conventional treatment(AbGenomics B.V Taiwan Branch)은 Graft vs Host Disease 표적 치료제로, Graft vs Host Disease 영역에서 개발·상용화 중입니다. 작용기전: targets and cellular pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 41.33% (ClinicalTrials.gov NCT03486457). 차별점: novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies.
Graft vs Host Disease
Graft vs Host Disease
Active
novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies
targets and cellular pathway
apoptosis, and changes in key cell markers were evaluated
PD-1 combination therapy follow
resistance towards conventional treatment techniques
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.